Malignant Neoplasm of the Endometrium B045
Current RMA Instruments:
| 31 of 2025 | |
| 32 of 2025 |
Changes from previous Instruments:
ICD Coding:
- ICD-10-AM Codes: C54.1
Brief description
Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old.
Confirming the diagnosis
Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty.
The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist.
Diagnoses covered by SOP
- Adenoacanthoma of the endometrium
- Adenocarcinoma of the endometrium
- Adenosquamous, clear cell and papillary serous carcinoma of the endometrium
- Carcinoma-in-situ of the endometrium
- Carcinosarcoma of the endometrium
- Malignant mesodermal mixed tumour of the endometrium
Conditions excluded from SOP
- Hodgkin's lymphoma of the endometrium *
- Leiomyoma (fibroid) of the uterus #
- Malignant neoplasm of the cervix *
- non-Hodgkin's lymphoma of the endometrium *
- soft tissue sarcoma of the endometrium *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue.
The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination.
Clinical worsening
For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/sops-grouped-icd-body-system/m/malignant-neoplasm-endometrium-b045-c541
Rulebase for malignant neoplasm of the endometrium
<h3><strong>Current RMA Instruments:</strong></h3><table border="1" cellpadding="1" cellspacing="1"><tbody><tr><td><address><p><a href="http://www.rma.gov.au/assets/SOP/2025/1137fb2412/031.pdf" target="_blank">Reasonable Hypothesis SOP</a></p></address></td><td>31 of 2025</td></tr><tr><td><address><p><a href="http://www.rma.gov.au/assets/SOP/2016/012.pdf" target="_blank">Balance of Probabilities SOP</a></p></address></td><td>32 of 2025</td></tr></tbody></table><h5>Changes from previous Instruments:</h5><drupal-media data-entity-type="media" data-entity-uuid="fd19f623-b278-40a8-8c49-73474c660209"> </drupal-media><h5> </h5><h5> ICD Coding:</h5><ul><li>ICD-10-AM Codes: C54.1</li></ul><h5>Brief description</h5><p>Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old. </p><h5>Confirming the diagnosis</h5><p>Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty. </p><p><span>The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist. </span></p><h5>Diagnoses covered by SOP</h5><ul><li>Adenoacanthoma of the endometrium</li><li>Adenocarcinoma of the endometrium</li><li>Adenosquamous, clear cell and papillary serous carcinoma of the endometrium</li><li>Carcinoma-in-situ of the endometrium</li><li>Carcinosarcoma of the endometrium</li><li>Malignant mesodermal mixed tumour of the endometrium</li></ul><h5>Conditions excluded from SOP</h5><ul><li>Hodgkin's lymphoma of the endometrium *</li><li>Leiomyoma (fibroid) of the uterus #</li><li>Malignant neoplasm of the cervix *</li><li>non-Hodgkin's lymphoma of the endometrium *</li><li>soft tissue sarcoma of the endometrium *</li></ul><p> </p><p>* another SOP applies - the SOP has the same name unless otherwise specified</p><p><font size="2"><sup>#</sup></font> non-SOP condition</p><h5>Clinical onset</h5><p><span>This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue. </span></p><p><span>The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination. </span></p><h5>Clinical worsening</h5><p><span>For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.</span></p><p> </p>
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/rulebase-malignant-neoplasm-endometrium
A course of therapeutic radiation involving the pelvic organs
Current RMA Instruments:
| 31 of 2025 | |
| 32 of 2025 |
Changes from previous Instruments:
ICD Coding:
- ICD-10-AM Codes: C54.1
Brief description
Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old.
Confirming the diagnosis
Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty.
The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist.
Diagnoses covered by SOP
- Adenoacanthoma of the endometrium
- Adenocarcinoma of the endometrium
- Adenosquamous, clear cell and papillary serous carcinoma of the endometrium
- Carcinoma-in-situ of the endometrium
- Carcinosarcoma of the endometrium
- Malignant mesodermal mixed tumour of the endometrium
Conditions excluded from SOP
- Hodgkin's lymphoma of the endometrium *
- Leiomyoma (fibroid) of the uterus #
- Malignant neoplasm of the cervix *
- non-Hodgkin's lymphoma of the endometrium *
- soft tissue sarcoma of the endometrium *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue.
The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination.
Clinical worsening
For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-endometrium-b045-c541/rulebase-malignant-neoplasm-endometrium/course-therapeutic-radiation-involving-pelvic-organs
Being nulliparous
Current RMA Instruments:
| 31 of 2025 | |
| 32 of 2025 |
Changes from previous Instruments:
ICD Coding:
- ICD-10-AM Codes: C54.1
Brief description
Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old.
Confirming the diagnosis
Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty.
The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist.
Diagnoses covered by SOP
- Adenoacanthoma of the endometrium
- Adenocarcinoma of the endometrium
- Adenosquamous, clear cell and papillary serous carcinoma of the endometrium
- Carcinoma-in-situ of the endometrium
- Carcinosarcoma of the endometrium
- Malignant mesodermal mixed tumour of the endometrium
Conditions excluded from SOP
- Hodgkin's lymphoma of the endometrium *
- Leiomyoma (fibroid) of the uterus #
- Malignant neoplasm of the cervix *
- non-Hodgkin's lymphoma of the endometrium *
- soft tissue sarcoma of the endometrium *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue.
The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination.
Clinical worsening
For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-endometrium-b045-c541/rulebase-malignant-neoplasm-endometrium/being-nulliparous
Hormonal replacement therapy
Current RMA Instruments:
| 31 of 2025 | |
| 32 of 2025 |
Changes from previous Instruments:
ICD Coding:
- ICD-10-AM Codes: C54.1
Brief description
Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old.
Confirming the diagnosis
Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty.
The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist.
Diagnoses covered by SOP
- Adenoacanthoma of the endometrium
- Adenocarcinoma of the endometrium
- Adenosquamous, clear cell and papillary serous carcinoma of the endometrium
- Carcinoma-in-situ of the endometrium
- Carcinosarcoma of the endometrium
- Malignant mesodermal mixed tumour of the endometrium
Conditions excluded from SOP
- Hodgkin's lymphoma of the endometrium *
- Leiomyoma (fibroid) of the uterus #
- Malignant neoplasm of the cervix *
- non-Hodgkin's lymphoma of the endometrium *
- soft tissue sarcoma of the endometrium *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue.
The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination.
Clinical worsening
For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-endometrium-b045-c541/rulebase-malignant-neoplasm-endometrium/hormonal-replacement-therapy
No appropriate clinical management for malignant neoplasm of endometrium
Current RMA Instruments:
| 31 of 2025 | |
| 32 of 2025 |
Changes from previous Instruments:
ICD Coding:
- ICD-10-AM Codes: C54.1
Brief description
Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old.
Confirming the diagnosis
Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty.
The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist.
Diagnoses covered by SOP
- Adenoacanthoma of the endometrium
- Adenocarcinoma of the endometrium
- Adenosquamous, clear cell and papillary serous carcinoma of the endometrium
- Carcinoma-in-situ of the endometrium
- Carcinosarcoma of the endometrium
- Malignant mesodermal mixed tumour of the endometrium
Conditions excluded from SOP
- Hodgkin's lymphoma of the endometrium *
- Leiomyoma (fibroid) of the uterus #
- Malignant neoplasm of the cervix *
- non-Hodgkin's lymphoma of the endometrium *
- soft tissue sarcoma of the endometrium *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue.
The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination.
Clinical worsening
For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-endometrium-b045-c541/rulebase-malignant-neoplasm-endometrium/no-appropriate-clinical-management-malignant-neoplasm-endometrium
Obesity
Current RMA Instruments:
| 31 of 2025 | |
| 32 of 2025 |
Changes from previous Instruments:
ICD Coding:
- ICD-10-AM Codes: C54.1
Brief description
Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old.
Confirming the diagnosis
Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty.
The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist.
Diagnoses covered by SOP
- Adenoacanthoma of the endometrium
- Adenocarcinoma of the endometrium
- Adenosquamous, clear cell and papillary serous carcinoma of the endometrium
- Carcinoma-in-situ of the endometrium
- Carcinosarcoma of the endometrium
- Malignant mesodermal mixed tumour of the endometrium
Conditions excluded from SOP
- Hodgkin's lymphoma of the endometrium *
- Leiomyoma (fibroid) of the uterus #
- Malignant neoplasm of the cervix *
- non-Hodgkin's lymphoma of the endometrium *
- soft tissue sarcoma of the endometrium *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue.
The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination.
Clinical worsening
For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-endometrium-b045-c541/rulebase-malignant-neoplasm-endometrium/obesity
Stein-Leventhal syndrome
Current RMA Instruments:
| 31 of 2025 | |
| 32 of 2025 |
Changes from previous Instruments:
ICD Coding:
- ICD-10-AM Codes: C54.1
Brief description
Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old.
Confirming the diagnosis
Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty.
The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist.
Diagnoses covered by SOP
- Adenoacanthoma of the endometrium
- Adenocarcinoma of the endometrium
- Adenosquamous, clear cell and papillary serous carcinoma of the endometrium
- Carcinoma-in-situ of the endometrium
- Carcinosarcoma of the endometrium
- Malignant mesodermal mixed tumour of the endometrium
Conditions excluded from SOP
- Hodgkin's lymphoma of the endometrium *
- Leiomyoma (fibroid) of the uterus #
- Malignant neoplasm of the cervix *
- non-Hodgkin's lymphoma of the endometrium *
- soft tissue sarcoma of the endometrium *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue.
The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination.
Clinical worsening
For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-endometrium-b045-c541/rulebase-malignant-neoplasm-endometrium/stein-leventhal-syndrome
Treatment with tamoxifen
Current RMA Instruments:
| 31 of 2025 | |
| 32 of 2025 |
Changes from previous Instruments:
ICD Coding:
- ICD-10-AM Codes: C54.1
Brief description
Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old.
Confirming the diagnosis
Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty.
The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist.
Diagnoses covered by SOP
- Adenoacanthoma of the endometrium
- Adenocarcinoma of the endometrium
- Adenosquamous, clear cell and papillary serous carcinoma of the endometrium
- Carcinoma-in-situ of the endometrium
- Carcinosarcoma of the endometrium
- Malignant mesodermal mixed tumour of the endometrium
Conditions excluded from SOP
- Hodgkin's lymphoma of the endometrium *
- Leiomyoma (fibroid) of the uterus #
- Malignant neoplasm of the cervix *
- non-Hodgkin's lymphoma of the endometrium *
- soft tissue sarcoma of the endometrium *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue.
The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination.
Clinical worsening
For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-endometrium-b045-c541/rulebase-malignant-neoplasm-endometrium/treatment-tamoxifen